Advert - GSK – CASE/0244/07/24

 

For producing prescribing information for Omjjara (momelotinib), a black triangle medicinal product subject to additional monitoring which was contraindicated in pregnancy, that was misleading regarding the need for women using hormonal contraceptives to take additional precautions to avoid pregnancy, GSK was ruled in breach of the following clauses of the 2021 Code:

Clause 2           - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1        - Failing to maintain high standards

Clause 6.1        - Producing misleading information